Viridian Therapeutics Prices Upsized $350 Million Concurrent Public Offerings of Convertible Notes and Common Stock

Viridian Therapeutics Prices Upsized $350 Million Concurrent Public Offerings of Convertible Notes and Common Stock

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, announced the pricing of its upsized underwritten public offering of $225.0 million aggregate principal amount of its 1.75% convertible senior notes due 2032 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and its upsized underwritten public offering of 7,352,942 shares of its common stock at a public offering price of $17.00 per share  (the “Equity Offering”).

WilmerHale represented the underwriters in the public offerings.

The WilmerHale team was led by Lisa Firenze and included Glenn Pollner, Jeffries Oliver-Li, Kevin Cheng, and Whitley Horning, with assistance from Barish Ozdamar and Bruce Manheim.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel